Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma
E Fernandez, W Cacheux, JL Frossard… - Digestive and Liver …, 2017 - Elsevier
Background Perioperative chemotherapy improves the prognosis of patients with
locoregionally advanced resectable gastric and gastro-esophageal junction …
locoregionally advanced resectable gastric and gastro-esophageal junction …
American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma: Systematic Review and Guidelines
R Kumar, L Tchelebi, CJ Anker, N Sharma… - American journal of …, 2022 - journals.lww.com
Objective: The objective of this study was to systematically evaluate the data regarding the
use of neoadjuvant, perioperative, surgical, and adjuvant treatment options in localized …
use of neoadjuvant, perioperative, surgical, and adjuvant treatment options in localized …
Comment on “To Treat, or Not to Treat, That is the Question Biomarker-guided Adjuvant Chemotherapy for Stage II and III Gastric Cancer”
3. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer
after D2 gastrectomy (CLASSIC): 5-year followup of an open-label, randomised phase 3 …
after D2 gastrectomy (CLASSIC): 5-year followup of an open-label, randomised phase 3 …
Leitlinienreport zur S3-Leitlinie Magenkarzinom–„Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs “
M Moehler, T Langer, T Bender, J Kofent… - Zeitschrift für …, 2019 - thieme-connect.com
89% der Teilnehmer waren zwischen 31 und 60 Jahren. Ca. 2/3 der Teilnehmer sind
männlich, 1/3 weiblich. ¾ der Ärzte arbeiteten in einem Lehrkrankenhaus oder einer …
männlich, 1/3 weiblich. ¾ der Ärzte arbeiteten in einem Lehrkrankenhaus oder einer …
[PDF][PDF] Current management of gastric cancer in Europe
IM Gramaticu, AE Croitoru - Chirurgia, 2018 - researchgate.net
Gastric cancer is one the most common maligancies and a considerable health problem
throughout the world. Multimodal approach, encompassing both radical surgery and …
throughout the world. Multimodal approach, encompassing both radical surgery and …
Clinical outcome in patients with carcinoma of the esophagogastric junction treated with neoadjuvant radiochemotherapy or perioperative chemotherapy: a two-center …
HV Wundsam, B Doleschal, R Prommer, C Venhoda… - Oncology, 2020 - karger.com
Background: Adenocarcinoma of the esophagogastric junction (AEG) is a rare but rising
tumor entity in the Western world. Treatment is complex, as multimodality is key to optimal …
tumor entity in the Western world. Treatment is complex, as multimodality is key to optimal …
The efficacy of adjuvant FOLFOX6 for patients with gastric cancer after D2 lymphadenectomy: A Propensity score-matched analysis
ZX Wang, XL Yang, MM He, F Wang, DS Zhang, YH Li… - Medicine, 2016 - journals.lww.com
Abstract Adjuvant 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX6) are widely used for
treating resected gastric cancer in clinics in China, but only few clinical trials have …
treating resected gastric cancer in clinics in China, but only few clinical trials have …
Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach?
X Chen, JR Eads, JB Ammori, AM Kumar… - Current oncology …, 2015 - Springer
Gastric cancer is one of the most prevalent and deadliest forms of cancer worldwide. Even
though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy …
though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy …
Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma
DK Lau, A Athauda, I Chau - Expert Opinion on Pharmacotherapy, 2021 - Taylor & Francis
Introduction: Gastric and esophageal adenocarcinoma is a leading cause of cancer-related
death globally. Surgery is the cornerstone modality for cure where feasible. Clinical studies …
death globally. Surgery is the cornerstone modality for cure where feasible. Clinical studies …